Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of

Subscriber access provided by University of Newcastle, Australia

Article

Enzyme-Cleavable Polymeric Micelles for the Intracellular De-livery of Pro-Apoptotic Peptides Hanna B Kern, Selvi Srinivasan, Anthony J. Convertine, David Hockenbery, Oliver W. Press, and Patrick S. Stayton Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b01178 • Publication Date (Web): 09 Mar 2017 Downloaded from http://pubs.acs.org on March 9, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Molecular Pharmaceutics

Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Pro-Apoptotic Peptides. Hanna B. Kern1, Selvi Srinivasan1, Anthony J. Convertine1, David Hockenbery2, Oliver W. Press2 and Patrick S. Stayton1. 1

Department of Bioengineering and Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA 98195 2 Fred Hutchinson Cancer Research Center, Seattle, WA, 98108 KEYWORDS: therapeutic peptide, apoptosis, cathepsin B, intracellular drug delivery, pH-responsive polymer, RAFT polymerization ABSTRACT: Peptides derived from the third Bcl-2 homology domain (BH3) renormalize apoptotic signaling by antagonizing prosurvival Bcl-2 family members. These potential peptide drugs exhibit therapeutic activities but are limited by barriers including short circulation half-lives and poor penetration into cells. A diblock polymeric micelle carrier for the BIM BH3 peptide was recently described that demonstrated anti-tumor activity in a B-cell lymphoma xenograft model [Berguig et al., Mol Pharm. 2012, 9, 3506-14]. However, the disulfide linkage used to conjugate the BIM peptide was shown to have non-optimal blood stability. Here we describe a peptide macromonomer composed of BIM capped with a four amino acid cathepsin B substrate (FKFL) that possesses high blood stability and is cleaved to release the drug inside of target cells. Employing RAFT polymerization, the peptide macromonomer was directly integrated into a multifunctional diblock copolymer tailored for peptide delivery. The first polymer block was made as a macro-chain transfer agent (CTA) and composed of a pH-responsive endosomolytic formulation of N,Ndiethylaminoethyl methacrylate (DEAEMA) and butyl methacrylate (BMA). The second polymer block was a copolymer of the peptide and polyethylene glycol methacrylate (PEGMA). PEGMA monomers of two sizes were investigated (300 Da & 950 Da). Protein gel analysis, high performance liquid chromatography and coupled mass spectrometry (MS) showed that incubation with cathepsin B specifically cleaved the FKFL linker and released active BIM peptide with PEGMA300 but not with PEGMA950. MALDI-TOF MS showed that incubation of the peptide monomers alone in human serum resulted in partial cleavage at the FKFL linker after 12 hours. However, formulation of the peptides into polymers protected against serum-mediated peptide degradation. Dynamic light scattering (DLS) demonstrated pH-dependent micelle disassembly (25 nm polymer micelles at pH 7.4 versus 6 nm unimers at pH 6.6), and a red blood cell lysis assay showed a corresponding increase in membrane destabilizing activity (< 1% lysis at pH 7.4 versus 95% lysis at pH 6.6). The full carrier-drug system successfully induced apoptosis in SKOV3 ovarian cancer cells in a dose-dependent manner, in comparison to a control polymer containing a scrambled BIM peptide sequence. Mechanistic analysis verified target-dependent activation of caspase 3/7 activity (8.1-fold increase), and positive annexin V staining (72% increase). The increased blood stability of this enzyme-cleavable peptide polymer design, together with the direct polymerization approach that eliminated post-synthetic conjugation steps, suggests that this new carrier design could provide important benefits for intracellular peptide drug delivery.

INTRODUCTION The overexpression of pro-survival B-cell lymphoma 2 (Bcl-2) proteins is a widespread mechanism of impaired apoptosis, tumorigenesis and resistance to chemotherapy1-4. Bcl-2 and its pro-survival relatives (Bcl-XL, Bcl-w, Mcl-1, Bcl-B, and Bfl1) inhibit apoptosis by binding and sequestering the pro-apoptotic proteins BAK and BAX, which normally initiate the apoptotic cascade by forming pores in the mitochondrial membrane and releasing cytochrome c5-6. In recent years, advanced understanding of apoptotic signaling has enabled the development of inhibitors of the pro-survival Bcl-2 proteins that mimic the third Bcl-2 homology domain (BH3) of their physiological antagonists7-13. Most notably, the selective Bcl-2 inhibitor ABT-199 showed encouraging results in early lymphoma clinical trials and was recently granted breakthrough therapy designation for the treatment of 17p deletion relapsed-

refractory chronic lymphocytic leukemia14-16. To date, other small molecule inhibitors with broader specificities (GX15070, ABT-101, ABT-263, ABT-737) have demonstrated only modest clinical benefits with significant dose-limiting toxicities. These findings demonstrate the promise of Bcl targets and corresponding pro-apoptotic peptides derived from the BH3 binding domain, which are advantageous in their simple design, high potency and predictable target specificity17-19. In particular, the peptide BIM is known to bind to all six prosurvival Bcl-2 proteins with high affinity20-21, and TAT-BIM and stapled-BIM peptides have been found to induce apoptosis in cancer cell lines and murine xenograft models with therapeutic benefits22-23. Unfortunately, a number of drug delivery barriers have limited the clinical application of peptide therapeutics such as BIM. Peptides have short circulation half-lives,

ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

are susceptible to degradation by extracellular proteases, and cross cell membranes with low efficiency thus limiting access to intracellular targets such as Bcl-2.

Figure 1. Design of a cathepsin B-cleavable diblock copolymer for the intracellular delivery and release of the pro-apoptotic peptide BIM. The first block drives micelle formation at physiological pH (7.4) and destabilizes membranes and facilitates endosomal escape at acidic pH values (5.8-6.6). The second block contains PEG units for biocompatibility and stability and a methacrylamido-peptide macromonomer consisting of BIM capped with a four amino acid (FKFL) cathepsin B substrate flanked on either side by a six carbon spacer (aminohexanoic acid (Ahx)). Cleavage at the FKFL linker by cathepsin B specifically releases BIM inside the endo/lysosomes of target cells. The full chemical structure of the diblock copolymer is depicted in Figure S3.

Previously, RAFT polymerization was employed to synthesize a series of pH-responsive diblock copolymers that improve the pharmacokinetic properties of biologic drugs (peptides, proteins, siRNA, mRNA, etc.) and facilitate endosomal escape to the cell cytosol24-33. One such carrier, conjugated to BIM through a reversible disulfide linkage, successfully enhanced its therapeutic activity in a murine xenograft model of human B-cell lymphoma34. A major limitation of this design was found to be the reducible disulfide linkage that displayed poor blood stability and compromised the full potential of the polymer-BIM conjuguates34. Disulfide linkers are designed to exploit the highly reducing cytosolic environment for intracellular drug release35, but have often demonstrated poor stability in the bloodstream36-39. Design of a polymer-peptide linker that is (a) highly stable in systemic circulation and (b) efficiently cleaved selectively in intracellular compartments could further enhance the quantity of BIM and other peptide/protein drugs reaching intracellular tumor targets. A peptide linker that is a selective substrate for a protease enriched in intracellular compartments is an alternative approach that meets both of the above criteria. Cathespin B is a cysteine protease that is preferentially localized in endo/lysosomal compartments40-43. Furthermore, cathepsin B-labile linkers have been utilized previously for other drug delivery applications including antibody-drug conjugates (ADCs) and degradable nucleic acid delivery vehicles44-47. A second drawback of the disulfide linkage is the added manufacturing complexity associated with post-synthetic pep-

Page 2 of 10

tide conjugation. Conjugation is especially challenging in the context of polyethylene glycol (PEG) grafts, which provide steric shielding properties, but also block access to pyridyl disulfide moieties during conjugation. To address both the stability and conjugation limitations of the disulfide linkage, a synthetic strategy has been employed that creates a selectively cleavable BIM peptide macromonomer (Figure 1). The macromonomer contains the BIM peptide sequence capped with the well-characterized cathepsin B substrate Phe-Lys-Phe-Leu (FKFL)47-52. This substrate is flanked on either side by a six carbon spacer (6-aminohexanoic acid (Ahx)) to facilitate steric access of the cathepsin enzyme in the context of the surrounding PEG grafts. The peptide is functionalized on its N-terminus with methacrylamide and directly and stably polymerized into a multifunctional diblock copolymer. The first polymer block is composed of a pH-responsive formulation that drives micelle formation at physiological pH and destabilizes membranes at the acidic pH values found within endosomes28-29. The second polymer block contains the peptide macromonomer and polyethylene glycol methacrylate (PEGMA) monomer for solubility and stability34, 53-55. Two different PEGMA monomers varying in length (300 Da & 950 Da) were investigated, but only PEGMA300 permitted cathepsin B access to the linker. In ovarian cancer cell cultures, the polymer was shown to facilitate intracellular BIM delivery and induce apoptosis in comparison to a scrambled BIM peptide sequence.

EXPERIMENTAL SECTION Synthesis and characterization of peptide macromonomers. Using an automated PS3 peptide synthesizer (Protein Technologies), the following peptides were synthesized on a solid support (rink amide MBHA resin (100-200 mesh), EMD Millipore) from FMOC protected (L) amino acids (EMD Millipore) and an FMOC protected 6aminohexanoic acid (Ahx) spacer (AnaSpec): AhxFKFLAhxMRPEIWIAQELRRIGDEFNAY (CathBIM), FLAhxMRPEIWIAQELRRIGDEFNAY (FLAhxBIM), and AhxFKFLAhxLRMREIIDAYERQFGEPNIWA (CathScrBIM). For the synthesis of corresponding methacrylamido-peptide monomers, the amino termini of the peptides were deprotected and functionalized with N-succinimidyl methacrylate (TCI America), while still linked to the resin. Two peptide monomers were synthesized: MaCathBIM and MaCathScrBIM. The peptides/monomers were deprotected/cleaved from the resin by treatment with trifluoroacetic acid/triisopropylsilane/H2O (9.5:2.5:2.5, v/v/v) for 4 hours and precipitated in cold ether. Crude peptides/monomers were purified by reverse phase high performance liquid chromatography (RP-HPLC) on a Jupiter 5 µm C18 300Å column (Phenomenx) with an Agilent 1260 HPLC. Ion trap mass spectrometry with electrospray (Bruker Esquire) was used to confirm the molecular weights of the purified products. RAFT synthesis of diblock copolymers. For synthesis of the diblock copolymers, a macroCTA consisting of N,N-diethylaminoethyl methacrylate (DEAEMA) and butyl methacrylate (BMA) was first polymerized under nitrogen in dioxane (50 wt% monomer) at 70 °C for 6 hours using 4-cyanopentanoic acid dithiobenzoate (CTP) as the chain transfer agent (CTA) and azobis(4-cyanopentanoic acid) (ABCVA) as the radical initiator. The molar composition of the reaction feed was 60% DEAEMA and 40% BMA, and the initial monomer ([M]o) to CTA ([CTA]o) to initiator ([I]o) ratio was 200:1:0.1. The resulting macroCTA, poly[(DEAEMA)-co-(BMA)], was purified by dialysis in acetone for 48 hours, followed by dialysis in water for 24 hours, and dried by lyophilization. The macroCTA was then employed for block copolymerization of PEGMA (MW = 300 Da, PEGMA300) and peptide macromonomer. Two different polymers were synthesized by varying the identity of the peptide monomer: poly[(DEAEMA)-co-(BMA)]-b-[(PEGMA300)-c-(MaCathBIM)] (PolCathBIM) and poly[(DEAEMA)-co-(BMA)]-b-[(PEGMA300)-c-


Page 3 of 10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(MaCathScrBIM)] (PolCathScrBIM). The block copolymerizations were conducted for 18 hours at 70 °C under nitrogen in an equal by volume mixture of dimethyl sulfoxide (DMSO) and dioxane (20 wt% monomer and macroCTA). The molar composition of the monomer feed was 96% PEGMA300 and 4% peptide monomer, and the [M]o:[mCTA]o:[I]o ratio was 45:1:0.1. The resulting diblock copolymers were precipitated 4X in a mixture of petroleum ether and diethyl ether (9:1, v/v) to remove unreacted PEGMA300 and solvents. To remove unreacted peptide, the polymers were redissolved in acetone, the peptide monomer was removed by centrifugation, and polymers were re-precipitated in petroleum ether. This two-step precipitation scheme was repeated 3X and the purified diblock copolymers were

lyophilized. For synthesis of PEGMA-peptide copolymers, the cathepsin B-cleavable BIM peptide macromonomer (MaCathBIM) was copolymerized with PEGMA300 (Pol300) or PEGMA950 (Pol950) under nitrogen in DMSO (20 wt% monomer) for 24 hours at 70 °C using CTP and ABCVA. The molar composition of the reaction feed was 4% peptide monomer and 96% PEGMA, and the [M]o:[CTA]o:[I]o ratios were 25:1:0.2 and 50:1:0.2 for Pol950 and Pol300, respectively. The resulting polymers were precipitated in diethyl ether and the unreacted peptide monomer was subsequently precipitated in acetone. This two-step precipitation scheme was repeated 6X and isolated polymers were lyophilized.

Table 1. Characterization of the cathepsin B-cleavable diblock copolymers (PolCathBIM & PolCathScrBIM) and peptide-PEGMA copolymers (Pol950 & Pol300). For the synthesis of diblock copolymers, a poly[(DEAEMA)-co-(BMA)] macroCTA was synthesized and employed for block copolymerization of PEGMA300 and MaCathBIM (PolCathBIM) or MaCathScrBIM (PolCathScrBIM). To investigate the effect of PEGMA chain length on cathepsin B cleavage, MaCathBIM peptide monomer was copolymerized with either PEGMA950 (Pol950) or PEGMA300 (Pol300). Polymer molecular weights (Mns) and molar mass dispersities (Đ) were determined by GPC. Molar compositions were determined by 1H-NMR and RP-HPLC analysis of reaction aliquots taken at to and tx. Polymer characterization by gel permeation chromatography (GPC), 1H-NMR and RP-HPLC. To measure the number average molecular weights (Mn) and molar mass dispersities (Đ) of the polymers, GPC was conducted using Tosoh SEC TSK GEL α-3000 and α4000 columns (Tosoh Bioscience), a 1200 Series liquid chromatography system (Agilent), and a miniDAWN TREOS three-angle light scattering instrument with an Optilab TrEX refractive index detector (Wyatt Technology). The mobile phase was 0.1 wt% lithium bromide in HPLC-grade N,N-dimethylformamide at 60 °C and a flow rate of 1 mL/min. The compositions of the macroCTA and diblock copolymers were determined by 1H-NMR spectroscopy (Bruker avance DRX 499) in CDCL3 and C2D6OS, respectively. For quantification of peptide content, reaction aliquots were collected at To and Tx and monomer depletion was measured by RP-HPLC (abs 280 nm). Formulation of polymer micelles. Aqueous polymer solutions were prepared in DMSO at 100 mg/mL and diluted into phosphate buffer saline (PBS) at 10 mg/mL. Serial dilutions were made and absorbance at 282 nm was measured to determine extinction coefficients. DMSO was removed by centrifugal dialysis in PBS (Amicon Ultra, 5 mL, 3K MWCO, Millipore), and final polymer concentrations were determined by UV spectrometry. Cathepsin B cleavage assay. Specific cleavage at the FKFL linker by cathepsin B was determined by adapting a method from Dubowchik et al.44 and Chu et al.47 Human liver cathepsin B (Enzo Life Sciences) was activated for 15 minutes in a solution of 0.158 mg/mL cathepsin B, 20 mM DTT, and 10 mM EDTA at 37 °C. Peptide or polymer was then solubilized in reaction buffer (10 mM phosphate, 1 mM EDTA, pH 6.6, 37 °C) and added to the enzyme solution for a final concentration of 1.28 µg/mL cathepsin B and 65 µM peptide/polymer. At various time points, reaction aliquots were removed, enzymatic activity was halted by addition of a thioprotease inhibitor (E-64 (Thermo Scientific), 26 µg/mL), and RP-HPLC and mass spectrometry were used to quantify cathepsin B cleavage of the FKFL linker. Cleavage of the polymers was also visualized by SDS-PAGE on 8-16% Tris-Glycine Gels (Bio-Rad). For protein gel analyses, reactions were conducted at 3X concentration and 160 µg of polymer was loaded per well.

Serum stability of peptide macromonomers and polymers. The stability of the peptide linker in the presence of serum proteases was evaluated by incubating the peptide monomers and polymers in human serum and analyzing the degradation products over time. A solution of peptide (40 mM, DMSO) or polymer (4 mM, PBS) was added to human serum to a final peptide/polymer concentration of 400 µM and incubated at 37 °C. At various time points, 40 µL aliquots of the mixture were withdrawn and 40 µL of acetonitrile was added to precipitate serum proteins and halt protease degradation. Precipitated solutions were centrifuged at 13,000 rpm for 10 min and supernatants were analyzed by MALDI-TOF MS using a Bruker Autoflex II. Sizing of micelles by dynamic light scattering. The hydrodynamic diameters of the polymer micelles were determined by dynamic light scattering (DLS) using a Nanoseries Zetasizer (Malvern). Measurements were taken of 0.25 mg/mL polymer solutions in 100 mM phosphate buffer (supplemented with 150 mM NaCl) at pH values ranging from 5.8 to 7.4. Mean particle diameter is reported as the number average + the half width of three independently prepared formulations. pH-responsive hemolysis assay. The ability of the polymers to induce pH-dependent membrane destabilization was assessed via a red blood cell hemolysis assay as described previously32-33. Briefly, polymers (60 µg/mL) were incubated for 1 hour at 37 °C with human red blood cells in a 100 mM phosphate buffer (supplemented with 150 mM NaCl) at pH values ranging from 5.8 to 7.4. Percent red blood cell lysis (hemolysis) was quantified by measuring hemoglobin release (abs 541 nm) relative to a 100% lysis control (0.1% Triton X100). Cell culture. SKOV3 human ovarian cancer cells (ATCC) were maintained in RPMI 1640 Medium with L-glutamine and HEPES supplemented with 10% FBS (GIBCO) and 1% penicillin/streptomycin (GIBCO). Cells were maintained in log-phase growth at 37 °C and 5% CO2. Cell Viability Assay. The cell killing activity of the polymers was initially evaluated using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega). SKOV3 cells were plated in a 96-well plate at a density of 7,000 cells per well and allowed to adhere for 24 hours. Cells were then incubated with 100 µL of polymer



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

solution at concentrations ranging from 0-10 µM for 96 hours. At 96 hours, cell viability was quantified by adding 20 µL of [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium (MTS) reagent to each well, incubating for 30 minutes, and measuring the absorbance at 490 nm using a plate reader. All experimental groups were run in triplicate and the results from three independent experiments were averaged. Caspase-3/7 Activity Assay. Caspase 3/7 activity was measured using a SensoLyte Homogenous AMC Caspase-3/7 Assay Kit (AnaSpec). SKOV3 cells were plated in a black 96-well plate with a clear bottom at a density of 7,000 per well and then treated with polymer (0-10 µM) for 72 hours. Assay reagents were mixed with cell culture medium as per the manufacturer’s instructions, incubated for 24 hours, and fluorescence (ex/em = 380nm/500nm) was measured using a plate reader. Percent caspase 3/7 activity was calculated relative to untreated cell cultures. Annexin V Apoptosis Assay. Induction of apoptosis was measured with a FITC Annexin V/Dead Cell Apoptosis Kit (Invitrogen) as per the manufacturer’s instructions. SKOV3s cells were plated in 6well plates at a density of 120,000 cells per well and treated with 10 µM polymer solutions for 72 hours. After 72 hours, cells were trypsinized, rinsed in PBS, centrifuged, stained with FITC-annexin V, and analyzed on a BD LSRII flow cytometer.

Page 4 of 10

RESULTS Synthesis and characterization of a cathepsin Bcleavable diblock copolymer for intracellular BIM delivery. A cathepsin B-cleavable BIM peptide macromonomer (MaCathBIM) was synthesized containing BIM capped with the cathepsin B substrate FKFL flanked on either side by a six-carbon spacer (Ahx). The peptide was functionalized on its N-terminus with methacrylamide for polymerization. A cathepsin B-cleavable peptide macromonomer containing a scrambled BIM sequence (MaCathScrBIM) was synthesized as a control. The molecular weights of the peptide macromonomers (3437 Da) were confirmed by mass spectrometry (Figure S1). Using RAFT polymerization, the peptide macromonomers were directly integrated into polymers designed to enhance peptide delivery. Targeted and experimentally determined polymer characteristics are summarized in Table 1. GPC and 1 H-NMR characterization data are included in SI (Figure S2,3)

Figure 2. Cathepsin B cleavage of the FKFL peptide linker. (A) Peptide monomers (MaCathBIM & MaCathScrBIM) and diblock copolymers made with PEGMA300 (PolCathBIM & PolCathScrBIM) were incubated with human liver cathepsin B (1.28 ug/mL) in 10 mM phosphate buffer (pH 6.6) at a concentration of 65 uM. At various timepoints the reactions were stopped by addition of E-64 thioprotease inhibitor (26 ug/mL) and reaction products were analyzed by RP-HPLC and MS. Cathepsin B rapidly and specifically cleaved the FKFL linker to release BIM. (B & C) Protein gel analysis of peptide-PEGMA copolymers (Pol300 & Pol950) following incubation with cathepsin B showed that (B) PEGMA950 hindered cathepsin B access to the FKFL linker, while (C) PEGMA300 permitted cleavage and peptide release from the polymer backbone. For protein gel analyses, enzymatic reactions were run at 3X concentrations and 3.6 nmol of polymer was loaded per well.

For the synthesis of pH-responsive diblock copolymers, a poly[(DEAEMA)-co(BMA)] macroCTA was synthesized with a molecular weight (Mn) of 16,600 g/mol and a narrow molar mass dispersity (Đ) of 1.07. A polymer formulation of 60% DEAEMA and 40% BMA was targeted, as this composition has been shown to possess optimal pH-responsive membrane destabilizing activity and trigger the endosomal release of biologic drugs28-29. For the second polymer block, PEGMA300 (96 mol%) and peptide macromonomer (4 mol %) were copolymerized. PEGMA300 was chosen as the hydrophilic stabilizing segment because the resultant copolymer, which contains the peptide macromonomer, is less sterically shielded from cathepsin B than longer PEGMA segments. Additionally, micelles with PEGMA300 hydrophilic stabilizers show enhanced pH-dependent endosomalytic activity relative to longer PEGMA950-based materials.34. Diblock copolymers containing either MaCathBIM (PolCathBIM) or MaCathScrBIM peptide (PolCathScrBIM) were synthesized. The molecular weights and Đs of PolCathBIM and PolCathScrBIM were determined

to be 28,700 Da and 29,300 Da, and 1.12 and 1.07, respectively. RP-HPLC analysis of aliquots collected at reaction start at end times was used to determine the peptide content of the polymers. PolCathBIM and PolCathScrBIM were found to contain 0.9 and 0.8 peptide units per polymer chain, respectively. To evaluate the effect of PEGMA monomer length on cathepsin B access to the FKFL linker, two copolymers were also synthesized containing the cathepsin B-cleavable BIM peptide monomer (MaCathBIM) and either PEGMA950 (Pol950) or PEGMA300 (Pol300). PEGMA950 and PEGMA300 contain 19 and 6 ethylene oxide units, respectively. The molar compositions of the copolymer feeds were 4% peptide monomer and 96% PEGMA. In order to produce polymers of roughly equal size, the degrees of polymerization (DP) were 25 and 50 for Pol950 and Pol300, respectively. The molecular weights of the copolymers were approximately 19,000 Da and molar mass dispersities were less than or equal to 1.08.


Page 5 of 10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Cathepsin B-mediated release of the pro-apoptotic peptide BIM. Cathepsin B is known to cleave the FKFL substrate between the lysine and C-terminal phenylalanine residues47. Consequently, cathepsin B cleavage of the peptide macromonomers (MW 3437 Da) at the FKFL linker should yield a 2980 Da product consisting of BIM or scrambled BIM modified on the N-terminus with FLAhx. To ensure the FLAhx modification did not impact BIM’s pro-apoptotic activity, the ability of FLAhxBIM to induce cytochrome C release from the mitochondria of granta-519 tumor cells was measured and compared to unmodified BIM. At a concentration of 10 µM, both FLAhxBIM and BIM induced >90% cytochrome c release (Figure S4) in comparison to a positive 1% Triton-X100 control. A negative control protein did not induce any measurable release of cytochrome c. To confirm cathepsin B-mediated cleavage of the FKFL linker, peptide macromonomers and diblock copolymers were incubated with human liver cathepsin B enzyme and degradation products were analyzed overtime by RP-HPLC and MS (Figure 2A). Cathepsin B rapidly and specifically cleaved MaCathBIM and MaCathScrBIM at the FKFL linker, with 100% cleavage observed by 20 minutes. Likewise, Cathepsin B cleaved PolCathBIM and PolCathScrBIM at the FKFL linker to release the desired (2980 Da) peptide product, although the kinetics of polymer cleavage were significantly slower than for the peptide monomers alone. In combination, these findings suggest cathepsin B will release active BIM peptide from its polymeric carrier within the endosomes of cancer cells. To evaluate the effect of PEGMA chain length on cathepsin B access to the FKFL linker, cathepsin B cleavage of Pol300 and Pol950 was analyzed by protein gel electrophoresis. Cathepsin B failed to cleave Pol950 at the FKFL linker with the BIM peptide band absent at time points ranging from 0 minutes to 24 hours (Figure 2B). In contrast, cathepsin B cleaved Pol300 similarly to the diblock copolymers (Figure 2C). It appears the longer-chain PEGMA950 sterically blocks cathepsin B access to copolymerized MaCathBIM peptide.

Figure 3. Stability of the FKFL linker in human serum. Peptide monomers/polymers (400 µM) were incubated in human serum and peptide products were extracted and analyzed by MALDI-TOF MS. Spectrum at 12 hours are shown. (A & C)

Peptide monomers (3437 Da) underwent low levels of cleavage at the FKFL linker to release FLAhxBIM, as indicated by the appearance of a 2980 Da peak. (B & D) In contrast, formulation into polymers prevented undesired cleavage of the FKFL linker by serum proteases.

Stability of the FKFL linker in human serum. To investigate the susceptibility of the FKFL peptide linker to extracellular protease degradation, the peptide macromonomers (MaCathBIM and MaCathScrbIM) and their corresponding diblock copolymers (PolCathBIM and PolCathScrBIM) were incubated in human serum at 37 °C. At timepoints ranging from 0 to 12 hours, peptide products were extracted into acetonitrile and analyzed by MALDI-TOF MS. For both MaCathBIM and MaCathScrBIM, intact peptide monomer (3437 Da) was detectable after 12 hours. However, low levels of cleavage at the FKFL linker did occur, with the slow appearance of a 2980 Da peak observed over time. The polymers were found to protect against degradation at the FKFL linker, as the 2980 Da peak was absent at all time points. Representative spectra after 12 hours are shown in Figure 3.

Figure 4. The diblock copolymers demonstrate pH-responsive membrane destabilizing activity. (A) Dynamic light scattering (DLS) was employed to measure particle diameters in phosphate buffers of varying pH. At pH 7.4 the polymers formed micelles, which disassembled into unimers of smaller diameter at more acidic pH values. (B) A red blood cell lysis assay demonstrated a corresponding increase in membrane destabilizing activity with a decrease in pH. Red blood cells were incubated with polymers (60 µg/mL) and % heme release (abs 541 nm) was quantified relative to a 0.1% TritonX-100 positive control.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Micelle sizing and pH-responsive membrane destabilizing activity. To confirm pH-dependent micelle formation, dynamic light scattering (DLS) was employed to measure particle sizes in phosphate buffers of varying pH (5.8-7.4) (Figure 4A). At pH 7.4, PolCathBIM and PolCathScrBIM assembled into micelles with hydrodynamic diameters of 25 nm and 26 nm, respectively. As the pH was decreased step-wise to 5.8, the micelles disassembled into unimers with diameters of 6 nm. Previously, the micellar morphology of closely related diblock copolymers was extensively characterized as a function of pH and buffer composition using surface tension and cryo-TEM measurements56. The polymers’ corresponding pH-responsive membrane destabilizing activity was evaluated using a red blood cell hemolysis assay (Figure 4B). The polymers (60 µg/mL) were incubated with red blood cells at varying pH values, and the release of heme groups (hemolysis) was measured spectrophotometrically (abs 541 nm). At pH 7.4, no significant red blood cell lysis was observed. However, as the pH was lowered to the values found in early (6.6) and late endosomes (5.8), a sharp increase in hemolysis was observed, with >95% lysis observed at pH 6.6. These findings demonstrate the potential of these polymers as pH-responsive intracellular delivery vehicles.

Page 6 of 10

Cancer cell viability. To assess the biological activity of PolCathBIM, a cytotoxicity study was conducted in SKOV3 ovarian cancer cells (Figure 5A) and 3T3 fibroblasts (Figure 5B) using an MTS cell viability assay. PolCathBIM potently induced SKOV3 cell death in a dose dependent fashion. After 96 hours of treatment with 10 µM PolCathBIM, only 25% of cells remained viable. In contrast, PolCathScrBIM exhibited minimal toxicity with greater than 90% cell viability observed at all polymer concentrations. In 3T3 fibroblasts, no BIMmediated cell death was observed. These findings suggest that BIM delivery specifically kills cancer cells with dysregulated Bcl-2 signaling. Induction of apoptotic markers: caspase 3/7 activity and annexin V staining. Activation of caspase-3 and caspase-7 is a critical step in the execution of apoptosis, which was measured using a profluorescent enzyme substrate. SKOV3 cells treated with polymer containing the active BIM sequence (PolCathBIM) exhibited a dose-dependent increase in caspase 3/7 activity (Figure 6A), with 10 µM PolCathBIM resulting in more than 8-fold greater activity. In contrast, cells treated with PolCathScrBIM showed no change relative to untreated cultures. Early in apoptosis, phosphatidylserine (PS) is translocated from the inner to outer plasma membrane, becoming exposed extracellularly. Consequently, apoptotic cells can be identified by staining with the human anti-coagulant annexin V, which binds to PS with high affinity. Treatment with PolCathBIM (10 µM) significantly increased annexin V staining of SKOV3s, with 87% of cells staining positive after 72 hours (Figure 6B). In contrast, only 15% of cells treated with PolCathScrBIM stained positive. In combination, these findings indicate that PolCathBIM kills cancer cells by inducing apoptosis.

Figure 5. PolCathBIM induces cell death in cultures of SKOV3 ovarian cancer cells. (A) In a dose-responsive manner, PolCathBIM reduced the viability of SKOV3 cells at 96 hours as measured by MTS assay. (B) In contrast, no activity was observed in non-cancerous 3T3 cell cultures after 120 hours of treatment.


Page 7 of 10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 6. PolCathBIM induces expression of apoptotic markers in SKOV3 ovarian cancer cells. (A) After 72 hours of polymer treatment, activation of caspase signaling was measured by addition of a pro-fluorescent caspase 3/7 substrate to cell cultures. Percent caspase 3/7 activity is reported relative to untreated cells. (B) After 72 hours of treatment with polymer (10 µM), FITCannexin V dye was added to SKOV3 cultures and flow cytometry was used to measure percent of cells stained positive.

DISCUSSION Peptides targeting pro-survival Bcl-2 proteins have been investigated as potential therapeutics for inducing apoptosis and/or restoring chemosensitivity in cancer. Before their activities can be tested clinically, a number of key limitations must be addressed including stability and half-life, tumor targeting, and efficient intracellular delivery. Due to their large size and polarity, peptides are unable to diffuse across cell membranes and reach intracellular drug targets on their own. In previous work, RAFT polymerization was employed to synthesize diblock copolymers tailored for peptide delivery33-34. The reported polymers contained a hydrophilic block for biocompatibility and peptide shielding in circulation, a pH-responsive block for escape from endosomes, and pyridyl disulfide groups for reversible disulfide conjugation to cysteine-containing drugs. These polymers successfully enhanced the intracellular delivery and activity of pro-apoptotic peptides in cancer cell cultures and a murine xenograft model of B-cell lymphoma33-34. It was the objective of this work to increase the stability of the polymer-peptide linkage through incorporation of a more stable peptide linker that is specifically cleaved within the endo/lysosomes of cancer cells. This objective was achieved through the synthesis and RAFT polymerization of a peptide

macromonomer containing the pro-apoptotic peptide BIM capped with a cathepsin B-labile peptide linker (Figure 1). Reducible disulfide linkers have been widely investigated for drug delivery. They aim to harness the high redox potential difference between the oxidizing extracellular environment and reducing intracellular environment for specific release inside cells. Unfortunately, disulfide linkers have often proven to be insufficiently stable in systemic circulation. In a pharmacokinetic study conducted in mice using dual-radiolabeled polymer-BIM conjugates, the peptide to polymer ratio in the blood dropped rapidly over the course of just hours and leveled off at ~45% of initial conjugation34. This drop occurred as the disulfide linker was reduced and BIM was released and cleared from circulation. These findings are consistent with reports using disulfide linkers in antibody-drug conjugates (ADCs), which estimate a linker half-life on the order of 24-48 hours36-39. Enzyme labile peptide linkers, specifically those cleaved by endo/lysosomal proteases, offer an alternative. These linkers are chemically stable in the bloodstream yet are rapidly and specifically cleaved upon internalization into target cells. Cathepsin B, a ubiquitous cysteine protease, is a demonstated candidate for this application. Cathepsin B is primarily localized in endo/lysosomes57, its cleavage substrates have been well-characterized47-52, and it is upregulated in a wide variety of cancers57. While Cathepsin B can be secreted in a variety of cancer cells57, it has previously been employed for the selective intracellular degradation of a polymer conjugate of the angiogenesis inhibitor TNP-47057,58 and a nucleic acid delivery vehicle47. In addition, selective intracellular cleavage by Cathepsin B is likely aided by the lysosomotropic nature of polymer drug conjugates57,59. As a linker, this work employed a four amino acid cathepsin B substrate, FKFL, that is rapidly cleaved between the lysine and C-terminal phenylalanine residues47. The substrate was flanked on each side by a six carbon spacer, 6-aminohexanoic acid (Ahx), to spatially separate the site of enzymatic cleavage from the peptide drug and polymer backbone. The N-terminus of the BIM peptide was capped with this linker, and the linkerpeptide sequence was subsequently functionalized with its Nterminus with methacrylamide for direct polymerization. Consequently, cathepsin B cleavage at the FKFL substrate would release a BIM peptide product modified on its N-terminus with FLAhx. To ensure this modification did not abrogate the pro-apoptotic activity of the BIM peptide, the ability of BIM and FLAhxBIM to induce the release of cytochrome C from the mitochondria of tumor cells was compared. Reassuringly, both BIM and FLAhxBIM exhibited potent cytochrome Creleasing activity in comparison to a negative control protein (Figure S4). Initially, there was also concern that the BIM peptide itself might undergo degradation by cathepsin B in the endo/lysosomal environment. Consequently, quantitative cathepsin B degradation of both BIM and the peptide monomer MaAhxFKFLAhxBIM was studied at pHs ranging from 5.07.2 using LC-MS. At pH 5.0, cathepsin B was found to cleave BIM between arginine (R) 64 and isoleucine (I) 65 (Figure S5A). However, cleavage of BIM occurred at a relatively slow rate, with only 50% of peptide cleaved after 30 minutes and 98% cleaved after 2 hours. In addition, cathepsin B cleavage of BIM did not occur at higher pH values (6.6 & 7.4). In contrast, incubation of MaAhxFKFLAhxBIM with cathepsin B resulted in rapid cleavage of the FKFL linker (approximately 99% cleavage after 20 min) that was insensitive to changes in



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

pH (Figure S5B). These results suggest that a window of opportunity exists for BIM to escape from endo/lysosomes between linker cleavage and endopeptide degradation. The MaAhxFKFLAhxBIM macromonomer was directly polymerized into a pH-responsive diblock copolymer (PolCathBIM) designed to enhance BIM’s pharmacokinetic and tumor delivery properties. The pH-responsive hydrophobic block consisted of DEAEMA and BMA and the hydrophilic block contained peptide and PEGMA300. This design bypasses the need for conjugation of peptide drugs in post synthetic steps. It also abrogates the difficulties of conjugating peptides to polymers displaying sterically stabilizing PEG grafts that make conjugation more difficult. However, the PEG grafts may also sterically impact the access of enzymes to the linker and thus the length of the PEG chains relative to the position of the linker in the peptide macromonomer construct must also be optimized. The rate of enzymatic cleavage was impacted in the polymer compared to the macromonomer, but greater than 94% of polymer cleavage was still complete by 2 hours with PEGMA300 (Figure 2A). Protein gel analysis showed that PEGMA950 effectively blocked cathepsin B access to the FKFL linker, while PEGMA300 did not (Figure 2B,C). Previous in vivo studies with the disulfide linked BIM peptide indicated that in those carriers the PEGMA950 constructs displayed better pharmaco-kinetics and tumor biodistribution. Thus these steric aspects require some competing optimization pressures. In the future, placing a longer and/or more hydrophilic spacer between the polymer backbone and enzyme substrate may permit cathepsin B access in the context of PEGMA950. Alternatively, block or copolymerizations of peptide, PEGMA300 and PEGMA950 might combine the strengths of the individual monomers. To assess the blood stability of the FKFL linker, the peptide monomers and PEGMA300 diblock copolymers (PolCathBIM & PolCathScrBIM) were incubated in human serum and the degradation products were analyzed over time by MALDITOF MS (Figure 3). The peptide monomers were found to cleave at the FKFL linker, but only at very low levels. Most importantly, extracellular degradation by serum proteases was abrogated by formulation into polymers, with cleavage products undetectable even at later time points. In combination, these findings suggest that the diblock copolymer design strikes an advantageous balance between protecting linker degradation in circulation and permitting cathepsin B access and peptide release upon internalization. The described macromonomer is proof-of-concept of this initial design, and investigation of alternative cathepsin B substrates may further enhance circulation stability. In particular, the dipeptide valine-citrulline is known to increase the circulation half-life of ADCs in comparison to phenylalanine-lysine60. The cathepsin B-cleavable BIM polymer potently induced cell death in SKOV3 ovarian cancer cells, in comparison to a control polymer containing an inactive peptide sequence (Figure 5A). A corresponding increase in caspase 3/7 activity and PS externalization (annexin V staining) was observed, indicating that the mechanism of cell death is BIM-mediated activation of the apoptotic cascade (Figure 6). In contrast, the BIMcontaining polymer did not exhibit bioactivity in 3T3 fibroblast cultures (Figure 5B). This demonstrates the potential of BIM for killing cancer cells while sparing healthy tissues. In this report, an enzyme-cleavable diblock copolymer was validated through initial in vitro characterization as an intra-

Page 8 of 10

cellular peptide carrier. The carrier offers two key advantages over previously employed disulfide linkages. First the cathepsin-labile peptide linker is highly stable in human serum and still efficiently cleaved inside target cells. Second, peptide incorporation via RAFT polymerization eliminates postsynthetic conjugation and substantially simplifies material manufacturing. Consequently, this work elucidates initial design strategies that balance blood stability and enzyme accessibility in the polymeric carrier. As such it represents an initial step towards realizing the promise of a number of therapeutic peptides with intracellular drug targets.

ASSOCIATED CONTENT Supporting Information The Supporting Information is available free of charge on the ACS Publications website.

AUTHOR INFORMATION Corresponding Author * Patrick S. Stayton, Department of Bioengineering, Box 355061, University of Washington, Seattle WA 98195, [email protected]

Author Contributions The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

ACKNOWLEDGMENTS The work was supported by the following NIH grants: F30 CA183263 (H.K.), T32 GM0072666 (H.K.), R01 CA158921-04 (D.H.), R21EB014572 (P.S.), R01CA109663 (O.P.), R01CA154897 (O.P.), R01CA076287 (O.P.), David and Patricia Giuliani Family Foundation (O.P.), Giuliani/Press Endowed Chair in Cancer Research (O.P.).

REFERENCES (1) Vaux, D.L.; Cory, S.; Adams, J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988, 335, 440-2. (2) Reed, J.C.; Kitada, S.; Takayama, S.; Miyashita, T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol. 1994, 5 (Suppl 1), 61-5. (3) Gascoyne, R.D.; Adomat, S.A.; Krajewski, S.; Krajewska, M.; Horsman, D.E.; Tolcher, A.W.; O'Reilly, S.E.; Hoskins, P.; Coldman, A.J.; Reed, J.C.; Connors, J.M. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997, 90, 244-51. (4) Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell. 2011, 144, 646-74. (5) Strasser, A.; Cory, S.; Adams, J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011, 30, 3667-83. (6) Lomonosova, E.; Chinnadurai, G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene. 2008, 27, S2-19. (7) Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J.C.; Pellecchia, M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003, 46, 4259-64. (8) Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.; Zhai, D.; Kipps, T.J.; Reed, J.C.; Pellecchia, M. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L). Chem Biol. 2004, 11, 389-95. (9) Verhaegen, M.; Bauer, J.A.; Martín de la Vega, C.; Wang, G.; Wolter, K.G.; Brenner, J.C.; Nikolovska-Coleska, Z.; Bengtson,


Page 9 of 10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


A.; Nair, R.; Elder, J.T.; Van Brocklin, M.; Carey, T.E.; Bradford, C.R.; Wang, S.; Soengas, M.S. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006, 66, 11348-59. (10) Nguyen, M.; Marcellus, R.C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju S.R.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R.W.; Beauparlant, P.; Shore, G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA. 2007, 104, 19512-7. (11) Joudeh, J.; Claxton, D. Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms. Expert Opin Investig Drugs. 2012, 21, 363-73. (12) Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R.; Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G.; Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005, 435, 677-81. (13) Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68, 3421-8. (14) Vandenberg, C.J.; Cory, S.; ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provokingthrombocytopenia. Blood. 2013, 121, 2285-8. (15) Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J. Dayton B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; Huang, D.C.; Hymowitz, S.G.; Jin, S.; Khaw, S.L.; Kovar, P.J.; Lam, L.T.; Lee, J.; Maecker, H.L.; Marsh, K.C.; Mason, K.D.; Mitten, M.J.; Nimmer, P.M.; Oleksijew, A.; Park, C.H.; Park, C.M.; Phillips, D.C.; Roberts, A.W.; Sampath, D.; Seymour, J.F.; Smith, M.L.; Sullivan, G.M.; Tahir, S.K.; Tse, C.; Wendt, M.D.; Xiao, Y. Xue, J.C.; Zhang, H.; Humerickhouse, R.A.; Rosenberg, S.H.; Elmore, S.W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013, 19, 202-8. (16) Peirs, S.; Matthijssens, F.; Goossens, S.; Van de Walle, I.; Ruggero, K.; de Bock, C.E.; Degryse, S.; Canté-Barrett, K.; Briot, D.; Clappier, E.; Lammens, T.; De Moerloose, B.; Benoit, Y.; Poppe, B.; Meijerink, J.P.; Cools, J.; Soulier, J.; Rabbitts, T.H.; Taghon, T.; Speleman, F.; Van Vlierberghe, P. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014, 124, 3738-47. (17) Lessene, G.; Czabotar, P.E.; Colman, P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008, 7, 9891000. (18) Cosulich, S.C.; Worrall, V.; Hedge, P.J.; Green, S.; Clarke, P.R. Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol. 1997, 7, 913-20. (19) Moreau, C.; Cartron, P.F.; Hunt, A.; Meflah, K.; Green, D.R.; Evan, G.; Vallette, F.M.; Juin, P. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem. 2003, 278, 19426-35. (20) Chen, L.; Willis, S.N.; Wei, A.; Smith, B.J.; Fletcher, J.I.; Hinds, M.G.; Colman, P.M.; Day, C.L.; Adams, J.M.; Huang, D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005, 17, 393-403. (21) Delgado-Soler, L.; Pinto, M.; Tanaka-Gil, K.; RubioMartinez, J. Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins. J Chem Inf Model. 2012, 52, 2107-18. (22) LaBelle, J.L.; Katz, S.G.; Bird, G.H.; Gavathiotis, E.; Stewart, M.L.; Lawrence, C.; Fisher, J.K.; Godes, M.; Pitter, K.; Kung, A.L.; Walensky, L.D. A stapled BIM peptide overcomes apop-

totic resistance in hematologic cancers. J Clin Invest. 2012, 122, 2018-31. (23) Kashiwagi, H.; McDunn, J.E.; Goedegebuure, P.S.; Gaffney, M.C.; Chang, K.; Trinkaus, K.; Piwnica-Worms, D.; Hotchkiss, R.S.; Hawkins, W.G. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol. 2007, 14, 1763-71 (24) Procko, E.; Berguig, G.Y.; Shen, B.W.; Song, Y.; Frayo, S.; Convertine, A.J.; Margineantu, D.; Booth, G.; Correia, B.E.; Cheng, Y.; Schief, W.R.; Hockenbery, D.M.; Press, O.W.; Stoddard, B.L.; Stayton, P.S.; Baker, D. A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell. 2014, 157, 1644-56. (25) Keller, S.; Wilson, J.T.; Patilea, G.I.; Kern, H.B.; Convertine, A.J.; Stayton, P.S. Neutral polymer micelle carriers with pHresponsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses. J Control Release. 2014, 191, 24-33. (26) Wilson, J.T.; Keller, S.; Manganiello, M.J.; Cheng, C.; Lee, C.C.; Opara, C.; Convertine, A.; Stayton, P.S. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013, 7, 3912-25. (27) Lundy, B.B.; Convertine, A.; Miteva, M.; Stayton, P.S. Neutral polymeric micelles for RNA delivery. Bioconjug Chem. 2013, 24, 398-407. (28) Manganiello, M.J.; Cheng, C.; Convertine, A.J.; Bryers, J.D.; Stayton, P.S. Diblock copolymers with tunable pH transitions for gene delivery. Biomaterials. 2012, 33, 2301-9. (29) Cheng, C.; Convertine, A.J.; Stayton, P.S.; Bryers, J.D. Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials. 2012, 33, 6868-76. (30) Berguig, G.Y.; Convertine, A.J.; Shi, J.; Palanca-Wessels, M.C.; Duvall, C.L.; Pun, S.H.; Press, O.W.; Stayton, P.S. Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibodypolymer conjugate. Mol Pharm. 2012, 9, 3506-14. (31) Palanca-Wessels, M.C.; Convertine, A.J.; Cutler-Strom, R.; Booth, G.C.; Lee, F.; Berguig, G.Y.; Stayton, P.S.; Press, O.W. AntiCD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol Ther. 2011, 19, 1529-37. (32) Convertine, A.J.; Benoit, D.S.; Duvall, C.L.; Hoffman, A.S.; Stayton, P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2009, 133, 221-9. (33) Duvall, C.L.; Convertine, A.J.; Benoit, D.S.; Hoffman, A.S.; Stayton, P.S. Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol Pharm. 2010, 7, 468-76. (34) Berguig, G.Y.; Convertine, A.J.; Frayo, S.; Kern, H.B.; Procko, E.; Roy, D.; Srinivasan, S.; Margineantu, D.H.; Booth, G.; Palanca-Wessels, M.C.; Baker, D.; Hockenbery, D.; Press, O.W.; Stayton, P.S. Intracellular delivery system for antibody-peptide drug conjugates. Mol Ther. 2015, 23, 907-17. (35) Meister, A.; Anderson, M.E. Glutathione. Annu Rev Biochem. 1983, 52, 711–760. (36) Thorpe, P.E.; Wallace, P.M.; Knowles, P.P.; Relf, M.G.; Brown, A.N.; Watson, G.J.; Knyba, R.E.; Wawrzynczak, E.J.; Blakey, D.C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 1987, 47, 5924-31. (37) Thorpe, P.E.; Wallace, P.M.; Knowles, P.P.; Relf, M.G.; Brown, A.N.; Watson, G.J.; Blakey, D.C.; Newell, D.R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988, 48, 6396403. (38) Xie, H.; Audette, C.; Hoffee, M.; Lambert, J.M.; Blättler, W.A. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004, 308, 1073-82. (39) Alley, S.C.; Benjamin, D.R.; Jeffrey, S.C.; Okeley, N.M.; Meyer, D.L.; Sanderson, R.J.; Senter, P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008, 19, 759-65.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

(40) Roberts, R. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. Drug News Perspect. 2005, 18, 60514. (41) Authier, F.; Métioui, M.; Bell, A.W.; Mort, J.S. Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem. 1999, 274, 33723-31. (42) Blum, J.S.; Fiani, M.L.; Stahl, P.D. Proteolytic cleavage of ricin A chain in endosomal vesicles. Evidence for the action of endosomal proteases at both neutral and acidic pH. J Biol Chem. 1991, 266, 22091-5. (43) Lautwein, A.; Kraus, M.; Reich, M.; Burster, T.; Brandenburg, J.; Overkleeft, H.S.; Schwarz, G.; Kammer, W.; Weber, E.; Kalbacher, H.; Nordheim, A.; Driessen, C. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin Sindependent manner. J Leukoc Biol. 2004, 75, 844-55. (44) Dubowchik, G.M.; Firestone, R.A.; Padilla, L.; Willner, D.; Hofstead, S.J.; Mosure, K.; Knipe, J.O.; Lasch, S.J.; Trail, P.A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002, 13, 855-69. (45) Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; Francisco, J.A.; Wahl, A.F.; Meyer, D.L.; Senter, P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003, 21, 778-84. (46) Shao, L.H.; Liu, S.P.; Hou, J.X.; Zhang, Y.H.; Peng, C.W.; Zhong, Y.J.; Liu, X.; Liu, X.L.; Hong, Y.P.; Firestone, R.A.; Li, Y. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study. Cancer. 2012, 118, 298696. (47) Chu, D.S.; Johnson, R.N.; Pun, S.H. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. J Control Release. 2012, 157, 445-54. (48) Cezari, M.H.; Puzer, L.; Juliano, M.A.; Carmona, A.K.; Juliano, L. Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides. Biochem J. 2002, 368(Pt 1), 365-9. (49) Cotrin, S.S.; Puzer, L.; de Souza Judice, W.A.; Juliano, L.; Carmona, A.K.; Juliano, M.A. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Anal Biochem. 2004, 335, 244-52. (50) Hasnain, S.; Hirama, T.; Tam, A.; Mort, J.S. Characterization of recombinant rat cathepsin B and nonglycosylated mutants expressed in yeast. New insights into the pH dependence of cathepsin B-catalyzed hydrolyses. J Biol Chem. 1992, 267, 4713-21. (51) Dubowchik, G.M.; Firestone, R.A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett. 1998, 8, 3341-6.

Page 10 of 10

(52) Stachowiak, K.; Tokmina, M.; Karpińska, A.; Sosnowska, R.; Wiczk, W. Fluorogenic peptide substrates for carboxydipeptidase activity of cathepsin B. Acta Biochim Pol. 2004, 51, 81-92. (53) Huang, C.; Neoh, K.G.; Xu, L.; Kang, E.T.; Chiong, E. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules. 2012, 13, 2513-20. (54) Lutz, J.F. Polymerization of oligo(ethylene glycol) (meth)acrylates: Toward new generations of smart biocompatible materials. J Polym Sci A: Polym Chem. 2008, 46, 3459–3470. (55) Pohlit, H.; Bellinghausen, I.; Schömer, M.; Heydenreich, B.; Saloga, J.; Frey, H. Biodegradable pH-Sensitive Poly(ethylene glycol) Nanocarriers for Allergen Encapsulation and Controlled Release. Biomacromolecules. 2015. (56) Cohen, N.; Binyamin, L.; Levi-Kalisman, Y.; Berguig, G.Y.; Convertine, A.; Stayton, P.; Yerushalmi Rozen, R. pH and Salt Effects on Surface Activity and Self-Assembly of Copolymers Containing a Weak Polybase. Langmuir. 2016, 36, 9286-92 (57) Mahamedd, M.M.; Sloane, B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006, 6, 764-75. (58) Satchi-Fainaro, R.; Puder, M.; Davies, J.W.; Tran, H.T.; Sampson, D.A.; Greene, A.K.; Corfas, G.; Folkman, J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 2004, 10, 255-61. (59) Vicent, M.J.; Duncan, R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24, 39-47. (60) Ducry, L.; Stump, B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010, 21, 5-13.

Graphic entry for the Table of Contents (TOC)


Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of

Recommend Documents